PHP8 AN ECONOMIC MODEL FOR COOPERATION BETWEEN A NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT PROGRAM:TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION  by Shavit, O et al.
467Abstracts
PHP8
AN ECONOMIC MODEL FOR COOPERATION
BETWEEN A NOT-FOR-PROFIT HMO AND A
PHARMACEUTICAL COMPANY IN A DISEASE
MANAGEMENT PROGRAM:TRANSFORMING
CONFLICT OF INTERESTS INTO UTILITY
MAXIMIZATION
Shavit O1, Raz M2, Chen M3, Blay A3, Friedman N2,
Hoffman A1
1Hebrew University of Jerusalem, Jerusalem, Israel; 2Maccabi
Healthcare Services,Tel-Aviv, Israel; 3Teva Pharmaceutical
Industries, Netanya, Israel
OBJECTIVES: When we come to examine the possibility
of cooperation between a pharmaceutical company and 
a not-for-proﬁt HMO for a clinical project, the conﬂict
of interests appears too obvious and substantial. A less
restrictive view might illuminate the possibility of using
each body’s relative advantages, channeling them towards
a common goal (using a proper contract), and thus 
maximizing each ﬁrm’s utility as well as society’s. The
objective of this work was to examine the ability of 
implementing such cooperation, and its outcomes.
METHODS: “Teva Pharmaceutical Industries LTD” and
“Maccabi Healthcare Services” cooperated in an asthma
disease management program in Israel. In order to over-
come conceptual obstacles, the ﬁrms’ managements had
a three-day workshop, organized by a neutral profes-
sional company. The two managements became familiar
with each other, learnt about each ﬁrm’s structure, capa-
bilities and relative advantages, learnt about possible
cooperation contracts and gained the will to examine a
cooperative disease management program. The contract
between Teva and Maccabi ensured that neither ﬁrm’s
interests would be jeopardized and that each ﬁrms
resources would be rationally allocated in order to
improve asthma treatment and overcome problems such
as supply-induced demand and cream skimming.
RESULTS: Clinical parameters of asthma treatment were
improved. Preventive treatment with steroids inhalers was
increased (from 25% of prescriptions to 33%), and
numbers of visits to the ER and hospitalizations were
decreased (from 89 and 75 annually to 56 and 55 respec-
tively). Average total cost per patient was reduced from
3365 NIS annually to 3182 NIS. Patients and physicians,
as well as managements, expressed great satisfaction with
the program. CONCLUSIONS: Cooperation between a
pharmaceutical company and a not-for-proﬁt HMO is
beneﬁcial. It is another step towards horizontal integra-
tion required for a higher quality managed care system.
Such cooperation could yield greater utility to each ﬁrm
and to society.
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OBJECTIVES: State funded healthcare systems, such 
as the UK, tend to be cautious with the diffusion of 
new drugs for fear of ﬁnancial pressures. One way of 
controlling diffusion, whilst maximising the beneﬁts for
patients, is to set up an outcome guarantee. This presen-
tation describes a case study using lipid lowering drugs,
recently completed. METHODS: The key stakeholders
were identiﬁed and each declared their interest on an
agreed matrix. This formed the basis of an outcome guar-
antee contract. Near patient testing and audit nurses were
used to identify at risk patients and enter them into an
agreed care pathway. Patients were given lifestyle advice,
re-tested and monitored every 3 months throughout the
18 months of the project. Results of treatment with lipid
lowering drugs were measured against their claimed 
beneﬁts and adjusted for concordance. If the drug under-
performed, according to agreed criteria, the pharmaceu-
tical company agreed to refund the cost of those drugs.
RESULTS: The concept was readily accepted by the
stakeholders. Two thousand at risk patients were identi-
ﬁed from one primary care trust, of which 1,400 were eli-
gible to enter the outcome guarantee. 600 patients to-date
have completed the project and ﬁnal results are due in
July. Of those who have completed the project, the major-
ity have reached target level and no refund has been due.
A qualitative evaluation of the stakeholders is currently
under way and will be reporting in August 2002. CON-
CLUSIONS: An outcome guarantee is an acceptable way
for a nationally funded health service to partner a phar-
maceutical company for optimal diffusion of drugs likely
to beneﬁt a patient population. The model has potential
for replication in other therapeutic areas and other
healthcare systems.
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